{"filing":{"accession_number":"0001493152-26-033594","cik":"0001855485","ticker":"CLDWW","company_name":"Calidi Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1855485/000149315226033594/form8-k.htm"},"events":[{"id":18520,"run_id":16648,"accession_number":"0001493152-26-033594","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses entry into a new lease agreement (Item 1.01) and termination of an existing lease (Item 1.02), with an estimated annual savings of $1.1 million in rent and facility-related expenses. While this involves material definitive agreements, it is primarily an operational/real estate transaction rather than a financial obligation in the traditional sense (debt issuance, covenant breach, etc.). The company is relocating to more cost-efficient premises, which is a strategic operational decision material to investors assessing the registrant's cost structure and operational efficiency.","company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDWW","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":17351,"accession_number":"0001493152-26-033594","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses entry into a new lease agreement (Item 1.01) and termination of an existing lease (Item 1.02), with an estimated annual savings of $1.1 million in rent and facility-related expenses. While this involves material definitive agreements, it is primarily an operational/real estate transaction rather than a financial obligation in the traditional sense (debt issuance, covenant breach, etc.). The company is relocating to more cost-efficient premises, which is a strategic operational decision material to investors assessing the registrant's cost structure and operational efficiency.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T21:31:39.395778+00:00","company_name":"Calidi Biotherapeutics, Inc.","ticker":"CLDWW","filing_date":"2026-07-16"}]}